Stool screening for colorectal cancer: Evolution from occult blood to molecular markers

Clinica Chimica Acta

Volumn 315, Issue 1-2, 2002, Pages 157-168

  Ahlquist, David A ^a   Shuber, Anthony P ^b  

^a MAYO CLINIC   (United States)

^b Exact Sciences Corporation   (United States)

Author keywords

Colorectal cancer; DNA markers; Stool screening

Indexed keywords

DNA MARKER;

CANCER SCREENING; COLONOSCOPY; COLORECTAL CANCER; DIAGNOSTIC ACCURACY; FECES ANALYSIS; GENETIC HETEROGENEITY; HEALTH CARE COST; HUMAN; LABORATORY DIAGNOSIS; MORTALITY; OCCULT BLOOD TEST; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; SIGMOIDOSCOPY; X RAY;

CLINICAL TRIALS; COLON; COLONIC POLYPS; COLONOSCOPY; COLORECTAL NEOPLASMS; DIAGNOSTIC ERRORS; DNA; FECES; FEMALE; GENETIC MARKERS; GUIDELINES; HUMANS; MALE; MASS SCREENING; OCCULT BLOOD; POINT MUTATION; SENSITIVITY AND SPECIFICITY; SIGMOIDOSCOPY;

EID: 0036132775     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-8981(01)00712-4     Document Type: Review

References (101)

1. Cancer statistics, 1998
2. U.S. Cancer incidence, mortality, and survival: 1973-1996
3. Colorectal cancer screening practices among primary care physicians in high-risk countries
4. 1989 Survey of physicians' attitudes and practices in early cancer detection
5. Screening for colorectal cancer. A comparison of 3 fecal occult blood tests
6. Sensitivity, specificity, and positive predictive value of the Hemoccult test in screening for colorectal cancers
7. Effect of rehydration on guaiac-based faecal occult blood testing in colorectal cancer screening
8. Dietary restriction impairs compliance with FOB screening for colorectal cancer
9. Patterns of occult bleeding in asymptomatic colorectal cancer
10. Guaiac immunochemical tests for faecal occult blood in colorectal cancer screening
11. Fecal occult blood testing for iron deficiency: A reappraisal
12. Detection of upper gastrointestinal blood with fecal occult blood tests
13. Population screening for colorectal cancer: Comparison between Guaiac and immunological faecal occult blood tests
14. A comparison of fecal occult blood tests for colorectal cancer screening
15. Accuracy of fecal occult blood screening for colorectal neoplasia: A prospective study using HemoQuant and Hemoccult
16. Fecal blood levels in health and disease: A study using HemoQuant
17. The "HemoQuant" test: A specific and quantitative determination of heme (hemoglobin) in feces and other materials
18. HemoQuant: A new quantitative assay for fecal hemoglobin: Comparison with Hemoccult
19. Randomised controlled trial of faecal occult blood screening for colorectal cancer
20. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study
21. Randomised study of screening for colorectal cancer with faecal occult blood test
22. Effect of fecal occult blood testing on mortality from colorectal cancer: A case control study
23. Fecal occult blood testing for colorectal cancer: Can we afford to do this?
24. Occult blood tests and colorectal tumors
25. A prospective study of diagnostic methods in adenoma follow up
26. Relative sensitivity of the fecal occult blood test and flexible sigmoidoscopy in detecting polyps
27. Sensitivity of fecal Hemoccult testing and flexible sigmoidoscopy for colorectal cancer screening
28. Screening for colorectal neoplasia in the Tel Aviv area: Cumulative data 1979-89 and initial conclusions
29. Can Hemoccult II replace colonoscopy after radical surgery for colorectal cancer or after polypectomy?
30. Faecal occult blood testing and colonoscopy in the surveillance of subjects at high risk of colorectal neoplasia
31. Interval cancers in a randomized controlled trial of screening for colorectal cancer using a fecal occult blood test
32. Screening colonoscopy in asymptomatic average-risk persons with negative fecal occult blood tests
33. Optimal dietary conditions for Hemoccult testing
34. Cost effectiveness model for colon cancer screening
35. Screening for colorectal cancer
36. The cost effectiveness of colorectal cancer screening in average risk adults
37. Prevention of colorectal cancer by flexible endoscopy and polypectomy: A case-control study of 32,702 veterans
38. A case control study of screening sigmoidoscopy and mortality from colorectal cancer
39. Screening sigmoidoscopy and colorectal cancer mortality
40. Sonnenberg A: Protection by endoscopy against death from colorectal cancer. A case control study among veterans
41. Triage by flexible sigmoidoscopy: Inevitably "short-sighted"
42. Screening for colorectal cancer by nurse endoscopists
43. In accuracy of endoscopists assessment of anatomical endpoint reached during screening flexible sigmoidoscopy; using a real-time magnetic imager
44. Colorectal carcinomas: Diagnostic implications of their changing frequency and anatomic distribution
45. Age and sex distribution of patients with colorectal cancer
46. Time trends in distal colorectal cancer subsite location related to age and how it affects choice of screening modality
47. Randomized trial of the addition of flexible sigmoidoscopy to faecal occult blood testing for colorectal neoplasia population screening
48. Barium enemas in carcinoma of the colon: Sensitivity of double and single contrast studies
49. Double contrast barium enema versus colonoscopy in the diagnosis of neoplastic disorders: Aspects of decision-making in general practice
50. Analysis of accuracy, complications, and cost of barium enema for CRC diagnosis
51. Barium enema versus colonoscopy for patients with polyps found during flexible sigmoidoscopy
52. Computed tomography colonography (virtual colonoscopy): A new method for colorectal screening
53. Detection of colorectal polyps by computed tomographic colography: Feasibility of a novel technique
54. A comparison of virtual and conventional colonoscopy for the detection of colorectal polyps
55. An initial experience with screening for colon polyps using spiral CT with and without CT colography (virtual colonoscopy)
56. Prevention of colorectal cancer by colonoscopic polypectomy
57. Screening reduces colorectal cancer rates in families with hereditary nonpolyposis colorectal cancer
58. Population-based surveillance by colonoscopy: Effect on the incidence of colorectal cancer. Telemark Polyp Study I
59. Stool markers for colorectal cancer screening: Future considerations
60. ELISA for occult fecal albumin
61. Fecal protein markers of colorectal cancer
62. Fecal lysozyme: An unreliable marker for colorectal cancer
63. Faecal lactoferrin, a novel marker of colorectal cancer in rats: A longitudinal in vivo study
64. Calprotectin: A sensitive marker of gastrointestinal neoplasia
65. Fecal marker variability in colorectal cancer: Calprotectin versus hemoglobin
66. Alterations in human colonic mucin occurring with cellular differentiation and malignant transformation
67. Heterogeneity of mucin gene expression in normal and neoplastic tissues
68. Mucin glycoproteins in gastrointestinal malignancies and metastasis
69. Mucin degradation in the human gastrointestinal tract and its significance to enteric microbial ecology
70. Assay of fecal MUC-1 for colorectal cancer detection: A feasibility study
71. Morphometric analysis of the "mucocellular layer" overlying colorectal cancer and normal mucosa: Relevance to exfoliated stool screening markers
72. Isolation of exfoliated colonic epithelial cells, a novel non-invasive approach to the study of cellular markers
73. Immunomagnetic isolation of malignant colonocytes from stool: Feasibility study in a model system
74. Quantitation of DNA from exfoliated colonocytes isolated from human stool surface as a novel noninvasive screening test for colorectal cancer
75. Evaluation of sensitivity and specificity of CD44 expression in fecal colonocytes as a noninvasive marker for detecting colonic polyps and cancer
76. Interference of fecal colonocyte recovery by endogenous cytolysis
77. A genetic model for colorectal tumorigenesis
78. Genetic instability and chromosomal aberrations in colorectal cancer: A review of current models
79. Molecular coproscopy: Dung and diet of the extinct ground sloth Notheriops shastensis
80. Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors
81. Detection of K-ras mutations in DNAs isolated from feces of patients with colorectal tumors by mutant-allele-specific amplification (MASA)
82. Detection of c-Ki-ras mutations in faecal samples from sporadic colorectal cancer patients
83. Identification of subjects at risk for colorectal carcinoma through a test based on K-ras determination in the stool
84. Detection of K-ras mutations in stools of patients with colorectal cancer by mutant-enriched PCR
85. Mutations of the p53 gene in stool of patients with resectable colorectal cancer
86. A highly sensitive method for K-ras mutation detection is useful in diagnosis of gastrointestinal cancer
87. Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia
88. Frequent and characteristic K-ras activation and absence of p53 protein accumulation in aberrant crypt foci of the colon
89. K-ras gene mutation in normal colorectal tissues from K-ras mutation-positive colorectal cancer patients
90. Colorectal cancer screening by detection of altered human DNA in stool: Feasibility of a multitarget assay system
91. Inhibitation of apoptosis during development of colorectal cancer
92. Rapid onset of apoptosis in vitro follows disruption of beta 1-integrin/matrix interactions in human colonic crypt cells
93. Programmed cell death: Concept, mechanism and control
94. Universal detection of aerodigestive cancers by assay of nonapoptotic human DNA in stool
95. American Cancer Society Guidelines for the early detection of cancer: Update of early detection guidelines for prostate, colorectal, and endometrial cancers
96. The best screening test for colorectal cancer - A personal choice
97. Discrete event simulation of the cost-effectiveness of colorectal cancer screening by a DNA-based stool test relative to current screening practice
98. CpG island methylator phenotype in colorectal cancer
99. A bird's eye view of global methylation